Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Developmental therapeutics

3058 - A phase I study evaluating DLYE5953A, an antibody-drug conjugate targeting the tumor-associated antigen lymphocyte antigen 6 complex locus E (Ly6E), in patients (Pts) with solid tumors


08 Oct 2016


Developmental therapeutics


Shanu Modi


Annals of Oncology (2016) 27 (6): 114-135. 10.1093/annonc/mdw368


S. Modi1, J.P. Eder2, P. Lorusso2, C. Weekes3, S. Chandarlapaty4, S.M. Tolaney5, J. McLaughlin2, D.R. Camidge6, C. Chang7, D. Nazzal7, S. Chen7, E. Schuth7, F. Brunstein7, W. Darbonne7, W. Flanagan7, A. Ungewickell7, G. Shapiro8

Author affiliations

  • 1 Medicine, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 2 Yale School Of Medicine, Yale Cancer Center, New Haven/US
  • 3 Department Of Medicine, University of Colorado Cancer Center Anschutz Cancer Pavilion, Aurora/US
  • 4 Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York/US
  • 5 Breast Oncology Center, Dana-Farber Cancer Institute, Boston/US
  • 6 Cancer Center, University of Colorado, Aurora/US
  • 7 Early Development, Genentech, Inc., 94080 - South San Francisco/US
  • 8 Early Drug Development Centre, Dana-Farber Cancer Institute, Boston/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3058


Ly6E is over-expressed in breast, lung, and pancreatic cancers. DLYE5953A is a humanized IgG1 anti-Ly6E monoclonal antibody conjugated to the potent anti-mitotic agent monomethyl auristatin E (MMAE), linked through the protease-labile linker MC-vc-PAB. DLYE5953A has the potential to selectively target Ly6E-expressing cancers.


This open-label, 3 + 3 dose-escalation study assessed safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity (RECIST v1.1) of DLYE5953A administered intravenously every 21 days (q3w) in pts with locally advanced or metastatic solid malignancies that had progressed on standard therapy. Tumor Ly6E expression was assessed by IHC and qRT-PCR.


As of 31 December 2015, 57 pts, median age 57 (range 33-82), received a median of 4 cycles of DLYE5953A (range 1-14). Escalating doses of DLYE5953A (0.2-2.4 mg/kg) were tested in 20 pts. No dose limiting toxicities were identified. The maximum administered dose of 2.4 mg/kg was tested further in 20 HER2-negative metastatic breast cancer (HER2- MBC) and 17 non-small cell lung cancer (NSCLC) pts. Primarily Grade 1-2 DLYE5953A-related adverse events (AEs) observed in 14/57 (>25%) of patients included: alopecia (53%), fatigue (49%), nausea (39%), anorexia (30%), and chills (28%). Grade ≥3 related AEs occurred in 14/57 (25%) of pts; neutropenia (7/57, 12%) was most frequent. Four pts discontinued DLYE5953A for AEs, and 4/44 pts (9%) underwent a dose reduction from 2.4 mg/kg for AEs. DLYE5953A demonstrated linear PK at ≥ 0.8 mg/kg by total antibody with low unconjugated MMAE levels in blood. Among pts who received ≥1 dose of 2.4 mg/kg DLYE5953A, partial responses (PR) were seen in 5 HER2- MBC (3 confirmed PRs; n = 26) and 4 NSCLC (1 confirmed PR, 2 PRs pending confirmation; n = 17) pts, with 8 pts remaining on treatment and enrollment ongoing.


DLYE5953A administered at 2.4 mg/kg has acceptable tolerability with manageable AEs and promising preliminary anti-tumor activity in NSCLC and MBC pts. Updated results including tumor LY6E expression analysis will be presented.

Clinical trial identification


Legal entity responsible for the study

Study sponsored by Genentech, Inc.


Study sponsored by Genentech, Inc.


S. Modi: Research funding from Genentech, Novartis, and Seattle Genetics. P. Lorusso: Honoraria from Genentech. C. Weekes: Research support from Genentech. S. Chandarlapaty: Honoraria from AstraZeneca and Chugai, grant support from Novartis and Lilly. S.M. Tolaney: Research funding from Genentech/Roche, Exelixis, Pfizer, Merck, Lilly, Novartis. D.R. Camidge: Honoraria from Roche. C-W. Chang, D. Nazzal, S-C. Chen, E. Schuth, F. Brunstein, W. Darbonne, W. Flanagan, A. Ungewickell: Roche employee and shareholder. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings